Invasion and metastasis of carcinomas is promoted by the activation of the embryonic 'epithelial to mesenchymal transition' (EMT) program, which triggers cellular mobility and subsequent dissemination of tumour cells. We recently showed that the EMT-activator ZEB1 (zinc finger E-box binding homeobox 1) is a crucial promoter of metastasis and demonstrated that ZEB1 inhibits expression of the microRNA-200 (miR-200) family, whose members are strong inducers of epithelial differentiation. Here, we report that ZEB1 not only promotes tumour cell dissemination, but is also necessary for the tumour-initiating capacity of pancreatic and colorectal cancer cells. We show that ZEB1 represses expression of stemness-inhibiting miR-203 and that candidate targets of miR-200 family members are also stem cell factors, such as Sox2 and Klf4. Moreover, miR-200c, miR-203 and miR-183 cooperate to suppress expression of stem cell factors in cancer cells and mouse embryonic stem (ES) cells, as demonstrated for the polycomb repressor Bmi1. We propose that ZEB1 links EMT-activation and stemness-maintenance by suppressing stemness-inhibiting microRNAs (miRNAs) and thereby is a promoter of mobile, migrating cancer stem cells. Thus, targeting the ZEB1-miR-200 feedback loop might form the basis of a promising treatment for fatal tumours, such as pancreatic cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncb1998DOI Listing

Publication Analysis

Top Keywords

emt-activator zeb1
8
zeb1 promotes
8
stemness-inhibiting micrornas
8
mir-200 family
8
family members
8
cancer cells
8
stem cell
8
cell factors
8
stem cells
8
cells
5

Similar Publications

Background: Oral squamous cell carcinoma (OSCC), an HPV-negative head and neck cancer, frequently metastasizes to the regional lymph nodes but only occasionally beyond. Initial phases of metastasis are associated with an epithelial-mesenchymal transition (EMT), while the consolidation phase is associated with mesenchymal-epithelial transition (MET). This dynamic is referred to as epithelial-mesenchymal plasticity (EMP).

View Article and Find Full Text PDF

The IGROVCDDP cisplatin-resistant ovarian cancer cell line is an unusual model, as it is also cross-resistant to paclitaxel. IGROVCDDP, therefore, models the resistance phenotype of serous ovarian cancer patients who have failed frontline platinum/taxane chemotherapy. IGROVCDDP has also undergone epithelial-mesenchymal transition (EMT).

View Article and Find Full Text PDF

Epithelial-to-mesenchymal transition (EMT) is a transcriptionally governed process by which cancer cells establish a front-rear polarity axis that facilitates motility and invasion. Dynamic assembly of focal adhesions and other actin-based cytoskeletal structures on the leading edge of motile cells requires precise spatial and temporal control of protein trafficking. Yet, the way in which EMT-activating transcriptional programs interface with vesicular trafficking networks that effect cell polarity change remains unclear.

View Article and Find Full Text PDF

Molecular monitoring of glioblastoma's immunogenicity using a combination of Raman spectroscopy and chemometrics.

Spectrochim Acta A Mol Biomol Spectrosc

May 2021

Dodd-Walls Centre for Photonics and Quantum Technologies, Department of Chemistry, University of Otago, Dunedin, New Zealand. Electronic address:

Raman spectroscopy (RS) has been used as a powerful diagnostic and non-invasive tool in cancer diagnosis as well as in discrimination of cancer and immune cells. In this study RS in combination with chemometrics was applied to cellular Raman spectral data to distinguish the phenotype of T-cells and monocytes after incubation with media conditioned by glioblastoma stem-cells (GSCs) showing different molecular background. For this purpose, genetic modulations of epithelial-to-mesenchymal transition (EMT) process and expression of immunomodulator CD73 were introduced.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the role of β1,3-Galactosyltransferase 5 (B3GALT5) in breast cancer, highlighting its association with disease progression and poor clinical outcomes, particularly in early-stage patients.
  • Using tissue samples from 202 women, the researchers found that higher levels of B3GALT5 correlated with shorter overall and relapse-free survival rates.
  • In vitro and in vivo experiments revealed that B3GALT5 promotes cancer cell behaviors such as migration, invasion, and epithelial-to-mesenchymal transition (EMT), underscoring its potential as a prognostic marker and therapeutic target in breast cancer treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!